News of the Day

A new survey commissioned by Pfizer has found that Australians increasingly view the risk of COVID-19 as the ‘new normal’.

The company's new executive strategy panel includes experienced senior industry leaders Bruce Goodwin, Melissa McGregor and Cheryl Maley.

A leading New Zealand advocacy group has welcomed the reimbursement of a biosimilar of breast cancer therapy, trastuzumab, but expressed disappointment at the failure to use a lower price to widen access.

Bristol Myers Squibb says the planned One-Stop Shop for clinical trials in Australia is an important step that needs to be supported with other reforms.

Parents are showing remarkable courage in sharing their personal stories of loss in an attempt to convince the Albanese government to implement a pre-election commitment. A typo means the planned diabetes tender will proceed simultaneously with the recently announced parliamentary inquiry. How? Are 60-day dispensing and other changes going the same way as other recent reforms?

Regenerative medicine company AVITA Medical (ASX:AVH) has announced that the US FDA has approved its premarket approval supplement for the use of the RECELL System to treat full-thickness skin defects.

A report from consulting firm RSM Australia has found that the speed and extent of the increase in maximum dispensed quantities will "cripple" community pharmacies.

Every community pharmacy will be impacted by the negative hit to dispensing remuneration. Yet not all can benefit from its reallocation to programs. This is partly because it is mostly a commitment to remunerate pharmacies for what they are already doing or to displace non-PBS revenue with official remuneration.

UK Prime Minister Rishi Sunak has announced a £40 million two-year pilot under which it will fund weight loss therapies as part of a plan to cut hospital waiting lists.

MSD has launched legal action against the US government, arguing that its planned introduction of a medicine price negotiation power is unconstitutional.

The TGA has approved Janssen's CAR-T therapy CARVYKTI (ciltacabtagene autoleucel) for blood cancer, and it will be considered again for funding in November.

The company said its multi-year relationship with para-athletes Curtis McGrath, Shae Graham, and Ben Popham, will see them work with Bupa to implement practical ways to expand the company's access and inclusion policies for its people and customers.